HUP0302050A3 - Pharmaceutical form of administration for peptides, method for its production and use - Google Patents

Pharmaceutical form of administration for peptides, method for its production and use

Info

Publication number
HUP0302050A3
HUP0302050A3 HU0302050A HUP0302050A HUP0302050A3 HU P0302050 A3 HUP0302050 A3 HU P0302050A3 HU 0302050 A HU0302050 A HU 0302050A HU P0302050 A HUP0302050 A HU P0302050A HU P0302050 A3 HUP0302050 A3 HU P0302050A3
Authority
HU
Hungary
Prior art keywords
peptides
administration
production
pharmaceutical form
pharmaceutical
Prior art date
Application number
HU0302050A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HUP0302050A2 publication Critical patent/HUP0302050A2/hu
Publication of HUP0302050A3 publication Critical patent/HUP0302050A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0302050A 2000-05-18 2001-05-16 Pharmaceutical form of administration for peptides, method for its production and use HUP0302050A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10024451A DE10024451A1 (de) 2000-05-18 2000-05-18 Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
PCT/EP2001/005555 WO2001087265A2 (de) 2000-05-18 2001-05-16 Pharmazeutische darreichungsform für peptide, verfahren zu deren herstellung und verwendung

Publications (2)

Publication Number Publication Date
HUP0302050A2 HUP0302050A2 (hu) 2003-09-29
HUP0302050A3 true HUP0302050A3 (en) 2012-11-28

Family

ID=7642584

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302050A HUP0302050A3 (en) 2000-05-18 2001-05-16 Pharmaceutical form of administration for peptides, method for its production and use

Country Status (25)

Country Link
US (2) US7718599B2 (hu)
EP (1) EP1282400B1 (hu)
JP (2) JP4944340B2 (hu)
KR (1) KR100580142B1 (hu)
CN (1) CN100342908C (hu)
AR (1) AR028588A1 (hu)
AU (1) AU777185B2 (hu)
BG (1) BG65976B1 (hu)
BR (1) BR0110892A (hu)
CA (1) CA2348167C (hu)
CZ (1) CZ303981B6 (hu)
DE (1) DE10024451A1 (hu)
HK (1) HK1058622A1 (hu)
HU (1) HUP0302050A3 (hu)
IL (1) IL152479A (hu)
MX (1) MXPA02011389A (hu)
NO (1) NO20025277D0 (hu)
NZ (1) NZ522381A (hu)
PL (1) PL203958B1 (hu)
RU (1) RU2253438C2 (hu)
SK (1) SK288118B6 (hu)
TW (1) TWI243059B (hu)
UA (1) UA74578C2 (hu)
WO (1) WO2001087265A2 (hu)
ZA (1) ZA200208761B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
JP4940492B2 (ja) * 2000-09-04 2012-05-30 大正製薬株式会社 鉄化合物配合内服液剤
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
CA2507524C (en) * 2002-09-27 2012-12-11 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
ES2297688T3 (es) * 2004-03-12 2008-05-01 Intercell Ag Procedimiento para solubizar mezclas de peptidos.
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006110118A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit cytoprotecteur
RU2358721C1 (ru) * 2005-04-15 2009-06-20 Виктор Павлович Кутняк Антинеопластический препарат (варианты)
WO2012077131A1 (en) * 2010-12-06 2012-06-14 Astron Research Limited A stable ready-to-use cetrorelix injection
CN102144980B (zh) * 2011-03-07 2013-01-09 深圳市健元医药科技有限公司 一种更加稳定的lhrh拮抗剂冻干粉针剂
CN106456704A (zh) * 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
UA127018C2 (uk) * 2017-01-31 2023-03-15 Веру Інк. КОМПОЗИЦІЇ ТА СПОСОБИ ТРИВАЛОГО ВИВІЛЬНЕННЯ АНТАГОНІСТІВ ГОНАДОТРОПІН-ВИВІЛЬНЯЮЧОГО ГОРМОНА (GnRH)
BR112021025558A2 (pt) * 2019-06-17 2022-03-03 Intas Pharmaceuticals Ltd Formulação estável de cetrorelix e processo para a preparação de uma formulação estável
RS62754B1 (sr) 2019-10-24 2022-01-31 Sun Pharmaceutical Ind Ltd Stabilan parenteralni dozni oblik cetroreliks acetata
WO2022269572A1 (en) 2021-06-25 2022-12-29 Extrovis Ag Pharmaceutical compositions
WO2023017326A1 (en) * 2021-08-11 2023-02-16 Rk Pharma Inc. Ready to use compositions of cetrorelix acetate

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE141996C (hu)
DD141996A1 (de) * 1979-02-21 1980-06-04 Ingrid Wolf Verfahren zur herstellung von lyophilisierten lhrh-praeparationen
JPS5892620A (ja) * 1981-11-28 1983-06-02 Sunstar Inc インタ−フエロン安定配合組成物
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
GB2218102B (en) * 1988-04-08 1992-09-16 Sandoz Ltd Calcitonin peptide derivatives
JPH0725662B2 (ja) * 1990-10-22 1995-03-22 アース製薬株式会社 使用時調製型上皮細胞成長因子含有水性薬剤の安定化方法
US5643878A (en) * 1991-09-12 1997-07-01 Ciba-Geigy Corporation 5-amino-4-hydroxyhexanoic acid derivatives
JP3608802B2 (ja) * 1991-09-20 2005-01-12 第一サントリーファーマ株式会社 安定なカルシトニン医薬組成物及びその製造法
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
JPH08502492A (ja) * 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 治療用ミクロエマルジョン
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
JP3636480B2 (ja) * 1993-05-19 2005-04-06 科研製薬株式会社 凍結乾燥製剤
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP2915296B2 (ja) * 1993-08-30 1999-07-05 宇野 潤 抗真菌製剤
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
EP1002529A1 (en) * 1994-09-09 2000-05-24 Takeda Chemical Industries, Ltd. Sustained-release preparation containing a metal salt of a peptide
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
DE726075T1 (de) * 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
AU5004196A (en) * 1995-03-10 1996-10-02 Boehringer Mannheim Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
DE19542837A1 (de) * 1995-11-17 1997-05-22 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung
US5942493A (en) * 1995-11-28 1999-08-24 Asta Medica Aktiengesellschaft LH-RH antagonists having improved action
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
IT1282733B1 (it) * 1996-05-20 1998-03-31 Flarer S A Composizioni farmaceutiche contenenti ciclosporina ed un veicolante comprendente almeno un estere dell'acido alfa-glicerofosforico
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
JP2001511153A (ja) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US20030162721A1 (en) * 1997-07-07 2003-08-28 Francesco Mehlem Pharmaceutical composition containing peptichemio
KR100389726B1 (ko) * 1998-03-06 2003-06-27 쥬가이 세이야쿠 가부시키가이샤 안정한 과립구 콜로니-자극 인자 함유 제제
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
WO2000015241A1 (fr) * 1998-09-11 2000-03-23 Chugai Seiyaku Kabushiki Kaisha Preparation d'une solution proteinique et son procede de stabilisation
EP0998940A1 (en) * 1998-09-30 2000-05-10 Laboratoire Theramex Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US6911455B2 (en) * 1999-12-22 2005-06-28 Smithkline Beecham Corporation Methods for preparing pharmaceutical formulations

Also Published As

Publication number Publication date
WO2001087265A3 (de) 2002-04-18
JP2003533466A (ja) 2003-11-11
JP4944340B2 (ja) 2012-05-30
CZ20023969A3 (cs) 2003-05-14
US20020039996A1 (en) 2002-04-04
KR100580142B1 (ko) 2006-05-16
IL152479A (en) 2013-08-29
PL363007A1 (en) 2004-11-15
CN100342908C (zh) 2007-10-17
EP1282400A2 (de) 2003-02-12
KR20030036179A (ko) 2003-05-09
NO20025277L (no) 2002-11-04
EP1282400B1 (de) 2016-12-14
NO20025277D0 (no) 2002-11-04
NZ522381A (en) 2004-07-30
US20050159335A1 (en) 2005-07-21
US7696149B2 (en) 2010-04-13
PL203958B1 (pl) 2009-11-30
BG65976B1 (bg) 2010-08-31
ZA200208761B (en) 2002-11-29
WO2001087265A2 (de) 2001-11-22
AU777185B2 (en) 2004-10-07
UA74578C2 (uk) 2006-01-16
DE10024451A1 (de) 2001-11-29
MXPA02011389A (es) 2003-04-25
RU2253438C2 (ru) 2005-06-10
TWI243059B (en) 2005-11-11
US7718599B2 (en) 2010-05-18
BR0110892A (pt) 2003-03-11
CA2348167A1 (en) 2001-11-18
JP2011213733A (ja) 2011-10-27
IL152479A0 (en) 2003-05-29
CA2348167C (en) 2012-01-10
AU7404101A (en) 2001-11-26
SK17162002A3 (sk) 2003-07-01
HK1058622A1 (en) 2004-05-28
AR028588A1 (es) 2003-05-14
SK288118B6 (sk) 2013-09-03
BG107312A (bg) 2003-06-30
CZ303981B6 (cs) 2013-07-31
HUP0302050A2 (hu) 2003-09-29
CN1469734A (zh) 2004-01-21
AU777185C (en) 2001-11-26

Similar Documents

Publication Publication Date Title
EP1365747A4 (en) PHARMACEUTICAL PRESENTATION OF ORAL PEPTIDE ADMINISTERED AND METHOD OF PRODUCTION
HUP0201711A3 (en) N-indanyl-benzamide derivatives, method for their production, their use and pharmaceutical preparations containing them
HUP0302050A3 (en) Pharmaceutical form of administration for peptides, method for its production and use
HK1077832A1 (en) 17a-ALKYL-17ß-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE FRODUCTION THEREOF, AND USE OF SAID 17a-ALKYL-17ß-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS
AU6271401A (en) Drug administering system and administering method
AU2682401A (en) Flavonoid drug and dosage form, its production and use
HUP0300209A3 (en) Lipid nanocapsules, preparation method and use as medicine
HUP0201010A2 (en) 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
HUP0303891A3 (en) Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them
IL160797A0 (en) ORAL PHARMACEUTICAL PRODUCTS CONTAINING 17beta-ESTRADIOL-3-LOWER ALKANOATE, METHOD OF ADMINISTERING THE SAME AND PROCESS OF PREPARATION
GB0017060D0 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
SG116507A1 (en) Pharmaceutical dosage form and method of making.
AU2003293593A8 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
HRP20031067A2 (en) Pharmaceutical formulation having masked taste and method for the production thereof
HUP0402602A3 (en) Method for preparing echinocandin derivatives, their use, pharmaceutical compositions comprising thereof and their intermediates
HUP0302429A3 (en) 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use
PL359208A1 (en) New derivatives of quinosoline, method of production of new derivatives of quinosoline and pharmaceutical preparations
IL145041A (en) Morpholine derivatives, methods for the production thereof and pharmaceutical preparations
AU2001254812A1 (en) 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations
IL154150A0 (en) Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts
AU2002210439A1 (en) Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
ZA200303276B (en) Stable pharmaceutical form of an anticancer drug and method for production of stable pharmaceutical form of an anticancer drug.

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ZENTARIS GMBH, DE

Free format text: FORMER OWNER(S): ZENTARIS AG, DE; ZENTARIS GMBH, DE

FD9A Lapse of provisional protection due to non-payment of fees